MP-376 safe and effective for treatment of P. aeruginosa in CF patients

May 16, 2010

A new possible treatment to treat P. aeruginosa in cystic fibrosis (CF) patients appears to be promising, according to research to be presented at the ATS 2010 International Conference in New Orleans.

Approximately 80 percent of CF patients develop chronic P. aeruginosa , and is an increasing problem. "New classes of inhaled antimicrobials are necessary to treat CF patients with chronic P. aeruginosa lung infection due to concerns for increased antimicrobial resistance, decreased efficacy and poor compliance/tolerability with currently available agents," said lead author of the research, Douglas Conrad, M.D., an associate professor of medicine at the University of California, San Diego.

To test the efficacy and safety on the new antibiotic called MP-376, a levofloxacin inhalation solution, the researchers recruited 151 CF patients and randomized them to receive MP-376 at three different dosing levels [120mg once a day (QD); 240 mg once a day, or 240mg twice a day (BID)] or placebo. Inhaled antimicrobials are known to be effective in lowering organism load in the airways and improving lung function in CF patients.

On average, the patients were 29 years old, had received almost five courses of inhaled antibiotics active against P. aeruginosa in the past year, were on multiple treatments to control their CF , and had just slightly more than 50 percent of predicted lung function for healthy individuals.

After 28 days of treatment, patients receiving MP-376 had reduced P. aeruginosa density in their sputum compared to those who had received placebo, and showed no evidence of antimicrobial resistance. The greatest significant treatment effect observed was in the patients who received the highest dose of MP-376 of 240mg twice a day. Eight patients discontinued the study, six due to adverse events. Of these six patients, two were in the placebo group, one in the 120mg QD, one in the 240mg QD and two in the 240mg BID group.

Lung function also improved in all the MP-376 groups with the greatest improvement being seen in those who received the 240mg BID dose, with an average improvement in FEV1% predicted of 10.9 percent over placebo. A similar effect was also seen in other measures of lung function.

Furthermore, treatment with MP-376 reduced the need for treatment with other anti-pseudomonal antimicrobials, with a 79 percent reduction over placebo in the MP-376 240mg BID group.

"MP-376 was well tolerated with no evidence of an increasing adverse event profile with increasing dose and adherence to MP-376 was very good with over 80 percent of patients in the study taking more than 90 percent of their drug," said Dr. Conrad.

While the reduction in P. aeruginosa density was expected, the degree of lung function improvement and reduction in the need for other antipseudomonal antimicrobials in this heavily treated patient population was unanticipated.

"The vast majority of patients were receiving dornase alpha, azithromycin and/or hypertonic saline, all of which on their own have been shown to improve lung function. Patients in the study had also received a mean of 4.8 courses of inhaled antimicrobials over the preceding 12 months, so a treatment effect of over 10 percent in percent predicted FEV1 in the MP-376 240mg BID group was unexpected," said Dr. Conrad.

Phase 3 trials are scheduled to begin later this year. "Positive findings in Phase 3, and subsequent regulatory approval, would provide CF clinicians with another important class of inhaled antimicrobials to treat CF lung disease," said Dr. Conrad. "Prevention of exacerbations and preservation of lung function are very important to patients with chronic P. aeruginosa lung infection and based on this study, we would expect similar results with MP-376 in Phase 3 studies. MP-376 would provide patients with a well tolerated inhaled antimicrobial that can be taken twice per day with a nebulization time of only 4-6 minutes, thus significantly lowering the treatment burden over currently available agents."

Explore further: Research gives new insights into rare disease of the inner ear

add to favorites email to friend print save as pdf

Related Stories

Treatment for mild asthma leads to improved lung function

Mar 10, 2008

A study by the Woolcock Institute of Medical Research in Sydney is the first to demonstrate that in patients with very mild or well-controlled asthma, regular treatment with low dose ICS leads to significantly better day–to-day ...

Garlic hope in infection fight

Jan 31, 2007

Garlic has been hailed a wonder drug for centuries and has been used to prevent gangrene, treat high blood pressure, ward off common colds and is even believed by some to have cancer-fighting properties.

Recommended for you

Thyroid disease risk varies among blacks, Asians, and whites

12 hours ago

An analysis that included active military personnel finds that the rate of the thyroid disorder Graves disease is more common among blacks and Asian/Pacific Islanders compared with whites, according to a study in the April ...

The key to easy asthma diagnosis is in the blood

15 hours ago

Using just a single drop of blood, a team of University of Wisconsin-Madison researchers has developed a faster, cheaper and more accurate tool for diagnosing even mild cases of asthma.

Younger adults hit hardest this flu season

17 hours ago

(HealthDay)—The H1N1 flu was the predominant influenza strain in the United States this year, but it packed a lot less punch than in 2009 when it caused a worldwide pandemic, health officials report.

User comments : 0

More news stories

Low Vitamin D may not be a culprit in menopause symptoms

A new study from the Women's Health Initiative (WHI) shows no significant connection between vitamin D levels and menopause symptoms. The study was published online today in Menopause, the journal of The North American Menopa ...

Tech giants look to skies to spread Internet

The shortest path to the Internet for some remote corners of the world may be through the skies. That is the message from US tech giants seeking to spread the online gospel to hard-to-reach regions.

Patent talk: Google sharpens contact lens vision

(Phys.org) —A report from Patent Bolt brings us one step closer to what Google may have in mind in developing smart contact lenses. According to the discussion Google is interested in the concept of contact ...

Wireless industry makes anti-theft commitment

A trade group for wireless providers said Tuesday that the biggest mobile device manufacturers and carriers will soon put anti-theft tools on the gadgets to try to deter rampant smartphone theft.